James Breslawski - Henry Schein CEO
| HSIC Stock | USD 73.26 0.50 0.69% |
CEO
Mr. James P. Breslawski, CPA is President, Vice Chairman of the Board of the Company. He was with the Company since 1980, in his current position as Vice Chairman since March 2018, President since 2005 and as a director since 1992. He is also a member of our Executive Management Committee. Mr. Breslawski held the position of Chief Executive Officer of our Global Dental Group from 2005 to March 2018. He also held the position of Executive Vice President and President of U.S. Dental from 1990 to 2005, with primary responsibility for the North American Dental Group. Between 1980 and 1990, Mr. Breslawski held various positions with us, including Chief Financial Officer, Vice President of Finance and Administration and Corporationrationrate Controller. Mr. Breslawski partners with our senior leadership team to address corporate and strategic priorities. Mr. Breslawski brings to the Companys Board of Directors management and leadership experience. The Board of Directors is aided by Mr. Breslawskis understanding of the health care business and his keen business acumen, leadership ability and interpersonal skills. Mr. Breslawski has served as Chairman of the Board of the American Dental Trade Association, Chairman of the Board of the Dental Trade Alliance Foundation and President of the Dental Dealers of America. He is also a member of the Leadership Council, School of Dental Medicine at Harvard University, a former board member of the Dental Life Network, a former member of the Board of Governors for St. Johns University and a former trustee of Long Island University. Mr. Breslawski is also a Certified Public Accountant. since 2018.
| Age | 70 |
| Tenure | 6 years |
| Address | 135 Duryea Road, Melville, NY, United States, 11747 |
| Phone | 631 843 5500 |
| Web | https://www.henryschein.com |
Henry Schein Management Efficiency
The company has return on total asset (ROA) of 0.0453 % which means that it generated a profit of $0.0453 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0888 %, meaning that it created $0.0888 on every $100 dollars invested by stockholders. Henry Schein's management efficiency ratios could be used to measure how well Henry Schein manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to 0.07. In addition to that, Return On Capital Employed is expected to decline to 0.10. At present, Henry Schein's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 219.4 M, whereas Total Current Assets are forecasted to decline to about 2.4 B.Similar Executives
| Found 2 records | CEO Age | ||
| Ryan Rhodes | EDAP TMS SA | 62 | |
| Marc Oczachowski | EDAP TMS SA | 54 | |
Management Performance
| Return On Equity | 0.0888 | ||||
| Return On Asset | 0.0453 |
Henry Schein Leadership Team
Elected by the shareholders, the Henry Schein's board of directors comprises two types of representatives: Henry Schein inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Henry. The board's role is to monitor Henry Schein's management team and ensure that shareholders' interests are well served. Henry Schein's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Henry Schein's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Ettinger, Senior Vice President - Corporate and Legal Affairs, Secretary | ||
| David McKinley, President Medical Group | ||
| Paul Rose, Senior Vice President Global Supply Chain | ||
| Norman Matthews, Independent Director | ||
| Philip Laskawy, Lead Independent Director | ||
| Steven Paladino, CFO, Executive VP and Executive Director | ||
| Ronald South, Senior CFO | ||
| Barry Alperin, Independent Director | ||
| Brad Connett, President - Henry Schein'sU.S. Medical Group | ||
| Shira Goodman, Independent Director | ||
| Lorelei McGlynn, Senior Vice President - Global Human Resources and Financial Operations | ||
| Bradley Sheares, Independent Director | ||
| Leonard David, Chief Compliance Officer, Senior Vice President | ||
| James Harding, CTO, Senior Vice President | ||
| Paul Brons, Independent Director | ||
| Lonnie Shoff, President and CEO of Global Animal Health and Strategic Partnerships Group | ||
| Gerald Benjamin, Chief Admin. Officer, Executive VP and Director | ||
| Bob Minowitz, President International Dental Group | ||
| Dianne Rekow, Director | ||
| Anne Margulies, Independent Director | ||
| Stanley Komaroff, Sr. Advisor | ||
| Mark Mlotek, Chief Strategic Officer, Executive VP and Director | ||
| Peter McCarthy, President - Global Animal Health Group | ||
| Bridget Ross, President of Global Medical Group | ||
| Kurt Kuehn, Independent Director | ||
| Christopher Pendergast, Senior Vice President CTO | ||
| James Breslawski, President, Executive Director and CEO of Global Dental Group | ||
| Elizabeth Rekow, Independent Director | ||
| Walter Siegel, Senior Vice President General Counsel | ||
| Graham Stanley, VP Officer | ||
| Jonathan Koch, Senior Vice President and CEO, Global Dental Group | ||
| Stanley Bergman, Executive Chairman and CEO | ||
| Joseph Herring, Independent Director | ||
| Olga Timoshkina, Chief Finance | ||
| Karen Prange, Executive Vice President; CEO of Global Animal Health, Medical and Dental Surgical Group | ||
| Carolynne Borders, Vice President - Investor Relations | ||
| Michael Racioppi, Senior Vice President Chief Merchandising Officer | ||
| Donald Kabat, Independent Director | ||
| Lawrence Bacow, Director | ||
| Louis Sullivan, Independent Director | ||
| Bradford Connett, Chief Group | ||
| Carol Raphael, Independent Director |
Henry Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Henry Schein a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0888 | ||||
| Return On Asset | 0.0453 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 13.42 B | ||||
| Shares Outstanding | 128.48 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 99.16 % | ||||
| Number Of Shares Shorted | 5.5 M | ||||
| Price To Earning | 17.39 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Henry Schein. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Henry Stock refer to our How to Trade Henry Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Henry Stock analysis
When running Henry Schein's price analysis, check to measure Henry Schein's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Henry Schein is operating at the current time. Most of Henry Schein's value examination focuses on studying past and present price action to predict the probability of Henry Schein's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Henry Schein's price. Additionally, you may evaluate how the addition of Henry Schein to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Henry Schein's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Henry Schein. If investors know Henry will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Henry Schein listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.62) | Earnings Share 3.16 | Revenue Per Share 94.466 | Quarterly Revenue Growth (0.10) | Return On Assets 0.0453 |
The market value of Henry Schein is measured differently than its book value, which is the value of Henry that is recorded on the company's balance sheet. Investors also form their own opinion of Henry Schein's value that differs from its market value or its book value, called intrinsic value, which is Henry Schein's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Henry Schein's market value can be influenced by many factors that don't directly affect Henry Schein's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Henry Schein's value and its price as these two are different measures arrived at by different means. Investors typically determine if Henry Schein is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Henry Schein's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.